Pernix Therapeutics Holdings has launched Omeclamox-Pak, a ten-day therapy, to eradicate Helicobacter pylori (H. pylori) in adult patients.

Omeclamox-Pak is composed of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg) for the treatment of H. pylori infection and duodenal ulcer disease.

Pernix sales and marketing vice president Chuck Hrushka said the company recruited a new sales force and established a targeted marketing program that will reach gastroenterology professionals in the coming months.

"We anticipate physicians and their patients will welcome the short, 10-day dosing regimen, especially when compared to other treatments," Hrushka added.

The triple combination medication which is taken orally consists of the protein pump inhibitor omeprazole and two broad spectrum antibiotics; clarithromycin tablets and amoxicillin capsules.